On Tuesday, April 18, 2017, the SMA community will be conducting a Patient-Focused Drug Development meeting with the Food and Drug Administration (FDA).
Through this Patient-Focused Drug Development (PFDD) meeting, the FDA provides a forum where SMA patients, families, and caregivers are invited to share their unique insight on the impact of SMA on their day-to-day lives. The FDA is also interested in gathering the SMA patients’ perspective on available treatment options and how well these may help to treat their symptoms, strategies for managing their SMA, and expectations for approved treatments for SMA, among other important topics.
At this meeting, several different groups of panelists, representing all types, ages and stages of SMA, will bring their voices and stories to depict the real and specific ways in which their lives are impacted by SMA. Each round of panelists will be followed by polling questions and a period of facilitated discussion.
There are two primary ways to participate in this meeting:
Attend in person. Registration for in-person attendance is free, but seating is limited and will be on a first-come, first-served basis. We strongly encourage in-person attendees to register well in advance.
View the webcast. A live-streaming webcast of the meeting will be available for those who are not able to travel to the meeting. The webcast is free, but you must register in advance.
Both in-person and webcast attendees will have an opportunity to submit comments during the discussion periods.
Date: April 18, 2017
Time: 8:00 AM - 5:00 PM EDT
Location: College Park Marriot Hotel and Conference Center, 3501 University Blvd East, Hyattsville, MD, 20783